– USA, CA – Cytokinetics, Incorporated (Nasdaq: CYTK) announced the appointment of Jim Daly to its Board of Directors effective August 19, 2025, bringing over 30 years of global biopharmaceutical leadership experience with particular expertise in commercialization to the Board.
About James M. Daly
Most recently, Jim Daly served as CCO at Incyte Corporation, where he led the launch of Jakafi and oversaw the development of the global commercial capabilities. Previously, he spent 10 years at Amgen, where he held multiple senior leadership positions, including SVP of North America Commercial Operations, and launched several successful medicines, including Neulasta, Xgeva, Nplate, and Vectibix.
Jim Daly began his career at GlaxoSmithKline, serving in escalating positions of seniority over his 16-year tenure with the company.
Jim Daly serves on the Boards of Madrigal Pharmaceuticals, argenx SE, and Acadia Pharmaceuticals.
Jim Daly earned a B.S. in Pharmacy and an M.B.A. from the University at Buffalo, SUNY.
About Cytokinetics
Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology to advance a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics is readying for potential regulatory approvals and commercialization of aficamten, a cardiac myosin inhibitor, following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in patients with obstructive hypertrophic cardiomyopathy (HCM). Aficamten is also being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF), ulacamten, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten, for the potential treatment of heart failure with preserved ejection fraction (HFpEF), and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.
For more: https://www.cytokinetics.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.